Floatz logo

Plerixafor

AML, Childhood

Washington University School of MedicineSmall moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the AML, Childhood cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Plerixafor is also rated in:

Fanconi anemiaDormant
BB
Indicative ·
70 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →